Audience Break-Down
100+
Attendees
40+
Leading Top Speakers
12+
Dedicated Networking Hours
50%
In-House Counsel
Highlights For This Year Include
- BPCIA Litigation Review: Discover the latest in Innovator vs Biosimilar litigation in the USA
- Enablement and Plausibility: Seek out the outcome of Amgen vs Sanofi and how it is shaping inhouse patent litigation strategy
- Obviousness Type Double Patenting: Enhance your patent extension strategy with an updated approach towards PTAs and PTEs
- Share your views at Patent Litigation Strategy 24 Roundtables: Trade Secret – ADC – Next-Gen Therapeutics: benchmark and share your views on the latest patent protection strategy.
- Skinny Label Case Law Review: Understand the Latest Strategies and Updates from Novartis and Recordati
Build Connections and Benchmark Alongside:
In-House Counsels in Pharma and Biotech
- General Counsel
- Global Head of IP
- Head of Patent Litigation
- VP-Intellectual Property
- Head of Legal/Legal Affairs
- Assistant General Counsel-IP
- Head of Global IP Strategy
- IP and Portfolio Management
- Patent Counsel
- Patent Litigation Counsel
- Divisional Counsel
Outside Counsels with Expertise in:
- Intellectual Property and Patent Law
- Hatch-Waxman Litigation
- Life Sciences
- Trade Secrets
- US Patent Law
- European Patent Law
100+
Attendees
40+
Leading Top Speakers
12+
Dedicated Networking Hours
50%
In-House General Counsel
